Agrin mediates chondrocyte homeostasis and requires both LRP4 and α-dystroglycan to enhance cartilage formation in vitro and in vivo by Eldridge, S et al.
EXTENDED REPORT
Agrin mediates chondrocyte homeostasis and
requires both LRP4 and α-dystroglycan to enhance
cartilage formation in vitro and in vivo
Suzanne Eldridge,1 Giovanna Nalesso,1 Habib Ismail,1 Karin Vicente-Greco,2
Panos Kabouridis,3 Manoj Ramachandran,4 Andreas Niemeier,5 Joachim Herz,6
Costantino Pitzalis,1 Mauro Perretti,7 Francesco Dell’Accio1
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2015-207316).
For numbered afﬁliations see
end of article.
Correspondence to
Suzanne Eldridge, Centre for
Experimental Medicine and
Rheumatology, William Harvey
Research Institute, Barts and
the London School of Medicine
and Dentistry, Queen Mary
University of London, London,
UK; s.e.eldridge@qmul.ac.uk
MP and FD’A are co-senior
authors.
Received 16 January 2015
Revised 14 May 2015
Accepted 14 July 2015
To cite: Eldridge S,
Nalesso G, Ismail H, et al.
Ann Rheum Dis Published
Online First: [please include
Day Month Year]
doi:10.1136/annrheumdis-
2015-207316
ABSTRACT
Objectives Osteoarthritis (OA) is a leading cause of
disability for which there is no cure. The identiﬁcation of
molecules supporting cartilage homeostasis and
regeneration is therefore a major pursuit in
musculoskeletal medicine. Agrin is a heparan sulfate
proteoglycan which, through binding to low-density
lipoprotein receptor-related protein 4 (LRP4), is required
for neuromuscular synapse formation. In other tissues, it
connects the cytoskeleton to the basement membrane
through binding to α-dystroglycan. Prompted by an
unexpected expression pattern, we investigated the role
and receptor usage of agrin in cartilage.
Methods Agrin expression pattern was investigated in
human osteoarthritic cartilage and following
destabilisation of the medial meniscus in mice.
Extracellular matrix (ECM) formation and chondrocyte
differentiation was studied in gain and loss of function
experiments in vitro in three-dimensional cultures and
gain of function in vivo, using an ectopic cartilage
formation assay in nude mice. Receptor usage was
investigated by disrupting LRP4 and α-dystroglycan by
siRNA and blocking antibodies respectively.
Results Agrin was detected in normal cartilage but
was progressively lost in OA. In vitro, agrin knockdown
resulted in reduced glycosaminoglycan content,
downregulation of the cartilage transcription factor SOX9
and other cartilage-speciﬁc ECM molecules. Conversely,
exogenous agrin supported cartilage differentiation in
vitro and ectopic cartilage formation in vivo. In the
context of cartilage differentiation, agrin used an
unusual receptor repertoire requiring both LRP4 and α-
dystroglycan.
Conclusions We have discovered that agrin strongly
promotes chondrocyte differentiation and cartilage
formation in vivo. Our results identify agrin as a novel
potent anabolic growth factor with strong therapeutic
potential in cartilage regeneration.
INTRODUCTION
Agrin (AGRN) is a heparan sulfate proteoglycan
known for its requirement in neuromuscular
synapse formation.1 Recent microarray data from
our laboratory identiﬁed agrin as a gene expressed
in cartilage and modulated upon injury,2 raising the
possibility of a novel function for agrin in an
aneural tissue such as cartilage, containing only one
cell type: the articular chondrocyte.
At the neuromuscular junction, neuronal agrin
(splice variant: y4, z8) binds low-density lipopro-
tein receptor-related protein 4 (LRP4) in a complex
with the muscle-speciﬁc kinase (MuSK) and
amyloid precursor protein family members APP
and APLP2 resulting in MuSK activation. This then
induces the aggregation of acetylcholine receptors
(AChRs),3–5 ensuring neuromuscular synapse for-
mation and maintenance. In other tissues, such as
the kidneys, lung and muscle, agrin (splice variant:
y0, z0) plays a role in mechanotransduction by
linking the cell cytoskeleton to other basement
membrane components including α-dystroglycan
(DAG1) and laminin-γ1 (LAMC1)6 7 through
either direct binding or indirectly through integ-
rins.8 More recent studies with transgenic mice
have demonstrated a non-redundant involvement
of agrin in postnatal skeletal development and
endochondral bone formation.9
The articular cartilage covers the ends of the
long bones at the joint and ensures frictionless
motion. Unlike the epiphyseal cartilage of the
developing skeletal elements, which is destined to
become calciﬁed, invaded by vessels and ultimately
replaced by bone through endochondral bone for-
mation, the articular cartilage is permanent
throughout life, is avascular and aneural and is
resistant to calciﬁcation, vascular invasion and
endochondral bone formation. Cartilage is mainly
composed of specialised extracellular matrix
(ECM) rich in collagen type II (COL2A1) and
highly sulfated proteoglycans, prevalently aggrecan
(ACAN), and chondrocytes which are sparsely
present throughout the abundant ECM.10
Chondrocyte differentiation and expression of
COL2A1 and ACAN is driven by the cartilage-
speciﬁc transcription factor SOX9.11
Under resting conditions, cartilage matrix has a
very low turnover (the half-life of COL2A1 is esti-
mated to be ∼117 years12); however, following
damage, the tissue deploys a homeostatic response,
supported by SOX9 upregulation and activity,
driving the replacement of the damaged ECM and
restoring cartilage integrity.2 13 When this
response is insufﬁcient or stunted, ECM break-
down takes place due to the release of proteolytic
enzymes including matrix metalloproteinases
(MMPs) and aggrecanases.14 Cartilage destruction
and the resulting joint failure are the hallmark of
osteoarthritis (OA), the most common cause of
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chronic disability worldwide after cardiovascular disease.15 16
During OA, chondrocytes acquire a phenotype similar to the
hypertrophic chondrocytes of the developing growth plate,
characterised by expression of collagen type X (COL10A1) and
MMP-13.17 18 The acquisition of this phenotype and the con-
sequent mineralisation drive cartilage breakdown.19 Therefore,
hypertrophic differentiation and calciﬁcation are important
mechanisms in OA progression. In spite of the huge social and
economic burden, we still have no cure for OA and strategies
for cartilage regeneration represent a priority in medical
research.
In this study we reveal a novel cell-autonomous reparative
autocrine/paracrine circuit with great therapeutic potential that
is governed by the homeostatic function of agrin in adult articu-
lar chondrocytes.
MATERIALS AND METHODS
Destabilisation of the medial meniscus
OA was induced in 8-week-old 129/Sv male mice by surgical
destabilisation of the medial meniscus (DMM) or sham surgery
to the contralateral limb as described previously20 and killed
after 8 weeks.
Cartilage harvest and chondrocyte isolation
Adult human articular cartilage was obtained from patients
undergoing joint replacement for knee OA after obtaining
informed consent. All procedures were approved by the East
London and The City Research Ethics Committee. Full thick-
ness cartilage was dissected from preserved areas of the femoral
condyles and the patellar groove. From each sample, one full
thickness specimen was processed for histological grading.
Bovine chondrocytes were isolated from the metatarsal joints of
18-month-old bovine obtained within 6 h of death from a local
abattoir. Full thickness sections were harvested for histological
analysis. Chondrocyte isolation and in vitro expansion was per-
formed as previously described.21
The full thickness explants taken for histological scoring were
ﬁxed in 4% paraformaldehyde in phosphate-buffered saline
(PBS) at pH 7.4, parafﬁn embedded, sectioned, stained and
scored for features of OA as described previously.22 23 All
experiments were performed using freshly isolated or conﬂuent
P0 cells.
Overexpression and siRNA transfection
Subconﬂuent cells were transfected with a plasmid encoding
agrin (COS7 and agrin plasmid were a kind gift from Dr M
Ferns, UC Davis Health System, USA), green ﬂuorescent protein
(GFP), bone morphogenetic protein (BMP)-2 (kind gift from Dr
Gerard Gross, Signaling and Gene Regulation, Gesellschaft für
Biotechnologische Forschung (GBF), Braunschweig, Germany),
LRP4 or siRNAs (20 nM) by using JetPrime transfection reagent
(PolyPlus Transfection, Illkirch, France) according to the manu-
facturer’s instructions. The cells were used in monolayer or
micromass. Observed transfection efﬁciency was 25%–30% for
C28/I2 and bovine chondrocytes; and around 95% for COS7
cells. siRNA oligo sequences can be found in online
supplementary table S1. A Stealth RNAi negative control duplex
of low guanine–cytosine (GC) content (Invitrogen) was used as
a negative control for agrin siRNA.
Micromass culture and Alcian blue staining
Cells were resuspended at a density of 2.0×107 cells/mL in com-
plete medium, and micromass cultures were obtained by pipet-
ting 15 mL drops of cell suspension into each well of a 24 well
plate. The cells were allowed to attach for 3 h and then 1 mL of
complete medium was added. Micromasses were cultured for
4 days, changing the medium every 48 h. Micromasses were har-
vested for RT-PCR gene expression analysis or ﬁxed and whole-
mount stained with Alcian blue.24 Alcian blue extraction and
quantiﬁcation was performed as previously described.25 Images
were acquired at room temperature with a camera (Coolpix
4500; Nikon), with the macrosetting and daylight. Image con-
trast was modiﬁed with Photoshop 7.0 for best graphic render-
ing, equally for all treatments.
Indirect immunoﬂuorescence
Immunocytochemistry and immunohistochemistry were per-
formed as previously described.25 For antigen retrieval on paraf-
ﬁn sections we used pepsin digestion.25 The primary anti-agrin
rabbit polyclonal antibody (Santa Cruz Biotechnology, Dallas,
Texas, USA) or the isotype-matched negative control normal
rabbit IgG (Dako, Ely, Cambridgeshire, UK) was diluted 1:200
in blocking buffer. Secondary antibodies were cy3-conjugated
goat anti–rabbit antibody diluted 1:300 ( Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania, USA)
for immunocytochemistry or goat anti-rabbit antibody Alexa
555 diluted 1:300 (Life Technologies) for immunohistochemis-
try. Slides were mounted in Mowiol (EMD Millipore,
Darmstadt, Germany), and images were acquired with a ﬂuores-
cence microscope (BX61; Olympus, Southend-on-Sea, UK)
using a Uplan-Fluor 40× NA 0.85 objective lens. Images were
acquired by using an F-View II Soft Imaging Solutions (SIS)
camera and Cell P software (Olympus). After acquisition, the
contrast of the images was enhanced for best graphic rendering
using Photoshop 7.0, all with the same parameters, without
altering the relationship of the target to control the images.
Total RNA extraction and real-time qPCR
Total RNA extraction, cDNA synthesis and real-time PCR were
performed as previously described.25 Real-time qPCR and
sequencing primers can be found in online supplementary tables
S2 and S3.
In vivo ectopic cartilage formation assay
The ectopic cartilage formation assay was performed as
described previously.21 In brief, for each injection 5 million
freshly isolated bovine chondrocytes were mixed with either
500 000 growth-arrested (treated with 7.5 mg/mL of
mitomycin-C (Sigma-Aldrich) diluted in complete medium for
2 h at 37°C) COS7 cells overexpressing FL-agrin or with the
same amount of mitomycin C-treated GFP transfected COS7
cells. Each sample was resuspended in 50 mL of sterile PBS and
injected intramuscularly in the posterior compartment of the
thigh of 3-week-old female CD1nu/nu mice.23 Twelve injections
per condition (24 in total) were performed. Animals were main-
tained in isolator cages under an unrestricted diet. The animals
were then killed after 2 weeks and the cartilage implants were
retrieved. All procedures were approved by the Local Ethics
committee and the UK Home Ofﬁce. The implants were
weighed and then parafﬁn embedded for histological analysis.
α-dystroglycan blocking
α-dystroglycan binding was inhibited in vitro on bovine chon-
drocytes in monolayer using 10 ng/mL α-dystroglycan antibody
(IIH6; Santa Cruz). Binding inhibition was conﬁrmed using
Phalloidin (Invitrogen) staining in PBS 1:1000. IgM (Santa
Cruz) was used as control antibody.
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Statistical analysis
Parametric data were compared with a student’s t test. p Values
<0.05 were considered signiﬁcant. *p<0.05; **p<0.005;
***p<0.0005. All the data in the graphs are expressed as mean
±SEM.
RESULTS
Agrin (y0, z0) is expressed in the articular cartilage and is
downregulated in OA
In the context of a transcriptomic analysis to identify genes
regulated by mechanical injury in cartilage,2 we discovered that
mRNA encoding for agrin and its receptors LRP4, APP, APLP2,
DAG1 and LAMC1 were expressed in human adult articular
cartilage (ﬁgure 1A) raising the question of whether agrin signal-
ling has a role in cartilage biology. MuSK, which is essential at
the neuromuscular junction, was not detected in two of three
samples.
At the neuromuscular junction, the presence of the alterna-
tively spliced inserts y and z results in a 1000-fold higher afﬁnity
of agrin to LRP4 and therefore neuromuscular synapse stability
via AChR clustering.4 To investigate whether these inserts (y4:
KSRK; z8:ELTNEIPA or 11:PETLDRSALFS or 19:
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Figure 1 Agrin (y0, z0) is expressed in the articular cartilage and reduced in OA. (A) Microarray analysis of agrin and its receptors DAG1, LAMC1,
LRP4, MuSK, APP and APLP2 in freshly dissected human articular cartilage samples. (B) Schematic representation of agrin (above) and sequence
analysis of agrin cDNA from human articular chondrocytes demonstrating the absence of the insert y and z (y0, z0) (below). (C) Agrin protein
detection in healthy human and bovine explants and in the murine joint of 129/Sv mice (n=3). F, femur; M, meniscus; T, tibia. (D) Agrin protein
detected on in isolated bovine articular chondrocytes and in C28/I2. (E) Agrin protein detection in paired human cartilage samples obtained from the
same joint, but either from persevered areas (Mankin score <4) or from severely affected areas (Mankin Score >8) (n=3). (F) Agrin protein detection
at 7 days and 8 weeks post DMM surgery in the joints of male 129/Sv mice; contralateral sham-operated joints served as control (n=3). AGRN,
agrin; DAG1, α-dystroglycan; DMM, destabilisation of the medial meniscus; GAG, glycosaminoglycan; LAMC1, laminin-γ1; LRP4, low-density
lipoprotein receptor-related protein 4; MuSK, muscle-speciﬁc kinase; OA, osteoarthritis.
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ELTNEIPAPETLDRSALFS) were present in chondrocytes, we
sequenced across the potential insert sites of agrin from human
articular chondrocyte cDNA. This analysis revealed, as in other
non-neural tissues, the absence of the alternatively spliced y and
z inserts in chondrocytes (ﬁgure 1B), where agrin has a pre-
ferred, but not exclusive, afﬁnity for dystroglycan binding com-
pared with the y4, z8 isoform.26
To investigate the expression pattern of agrin in normal joints
we used immunoﬂuorescence. Agrin was abundantly detected in
human, bovine and murine cartilage and menisci (ﬁgure 1C);
agrin protein was retained in vitro in isolated primary bovine
chondrocytes and in the human chondrocyte cell line C28/I227
in monolayer (ﬁgure 1D) and in three-dimensional culture (see
online supplementary ﬁgure S1). In the mouse, agrin was
detected within the superﬁcial and deep layers of the articular
cartilage, within the osteoid in the subchondral bone, and in the
menisci. In healthy human and bovine cartilage agrin expression
was distributed uniformly. However, in human OA cartilage,
agrin expression was markedly reduced (almost undetectable) in
the more severely affected areas (Mankin score >8) compared
with the relatively preserved ones (Mankin score <4) (ﬁgure
1E). In a validated murine model of OA induced by surgical
DMM,20 agrin expression was rapidly reduced in the articular
cartilage as early as 7 days after surgery, reaching undetectable
levels after 8 weeks (ﬁgure 1F).
Agrin cell autonomously regulates the chondrocyte
transcription factor SOX9
The downregulation of agrin in OA cartilage prompted us to
investigate whether agrin could have a function in chondrocyte
differentiation and ECM formation. To investigate whether
agrin has a cell-autonomous function in chondrocytes we
applied a loss of function approach. Silencing agrin in C28/I2
chondrocytes using either of two independent siRNA oligo-
nucleotide pairs (siRNA-1 and siRNA-2), we obtained a reduc-
tion of agrin mRNA by 59% and 78% respectively, allowing
dose–response experiments (ﬁgure 2A). Agrin knockdown
resulted in a dose-dependent decrease of absolute sulfated glyco-
saminoglycan (GAG) content in C28/I2 micromass cultures as
evaluated by Alcian blue staining24 (ﬁgure 2B). Total DNA
content was not changed, thereby suggesting that such differ-
ence did not result from a decreased cell number (ﬁgure 2C).
Agrin silencing also resulted in reduced expression of the car-
tilage transcription factor SOX9 mRNA (ﬁgure 2D) and dose-
dependent downregulation of its transcriptional targets
COL2A1 and ACAN mRNA (ﬁgure 2E, F).
Conversely, overexpression of full length agrin (y0, z0) in
bovine primary chondrocytes resulted in signiﬁcantly increased
sulfated GAG content compared with GFP-transfected controls,
both as total amount per micromass (ﬁgure 3A) and when nor-
malised for DNA content (ﬁgure 3B). Moreover, after 5 days
culture, SOX9 mRNA was signiﬁcantly upregulated and 2 days
later so were its direct transcriptional targets COL2A1 and
ACAN (ﬁgure 3C–E).28
These data also demonstrate that agrin function is cell
autonomous as it takes place in vitro, in the absence of potential
exogenous sources of agrin (eg, nerves).
Exogenous agrin supports formation of stable, hyaline-like
cartilage in vivo
In vitro cartilage formation is not always predictive of cartilage
formation in vivo.29 For instance, mesenchymal stem cells can
form cartilage in vitro, yet fail to form stable cartilage tissue in
vivo even following in vitro differentiation.29 To conﬁrm the
anabolic function of agrin in vivo, we used a highly stringent
transplantation model in which bovine articular chondrocytes
form stable hyaline cartilage resistant to vascular invasion and
endochondral bone formation when injected ectopically, in sus-
pension, into the muscle of immunodeﬁcient mice.23 29 This
validated model predicts clinical efﬁcacy of cell preparations for
cartilage repair in humans,30 and allows robust quantiﬁcation
and monitoring of gene expression.23
In order to administer exogenous agrin to the implanted
chondrocytes for the entire duration of the assay we used a pre-
viously validated strategy4 based on co-implantation of
growth-arrested, agrin-overexpressing COS7 cells (ratio 10:1) or
with GFP-overexpressing COS7 cells as control (see online sup-
plementary ﬁgure S3). Two weeks after implantation, the
implants exposed to agrin were signiﬁcantly larger than those
exposed to GFP (ﬁgure 4A–C) as determined by histomorpho-
metry (ﬁgure 4A, B) and wet weight (ﬁgure 4C) and with a
larger differentiated area as determined by increased area of
Safranin O metachromatic staining (ﬁgure 4A, D), but without
evidence of excessive accumulation of proteoglycans (ﬁgure 4E).
Figure 2 Agrin silencing by siRNA in
C28/I2 resulted in reduced
glycosaminoglycan content and
reduced expression of chondrocyte
differentiation markers. (A) Real-time
PCR analysis showing agrin
knockdown efﬁciency with agrin
siRNA1 or siRNA2 in C28/I2
chondrocytes; scrambled siRNA served
as control. (B) Micromass staining with
Alcian blue and spectrophotometric
quantiﬁcation following guanidine
extraction expressed as total value (C)
and normalised by DNA content. (D–F)
Real-time PCR analysis of SOX9, ACAN
and COL2A1 mRNA expression. Data
are mean±SEM, n=4. *p<0.05;
**p<0.005; ***p<0.0005 (unpaired
t test). ACAN, aggrecan; AGRN, agrin;
COL2A1, collagen type II.
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Similar data were obtained using toluidine blue staining (ﬁgure
4H). No vascular invasion was detected with Masson’s tri-
chrome staining and no calciﬁcation was detected with alizarin
red staining (ﬁgure 4I, J). Gene expression analysis performed
with bovine-speciﬁc primers showed no increased expression of
COL10A1 and MMP-13 in the agrin-treated group compared
with control (ﬁgure 4F, G).
Agrin-induced upregulation of SOX9 is α-dystroglycan and
LRP4 dependent
At the neuromuscular junction, neuronal agrin (y4, z8) binds to
LRP4 and signals through MuSK, while in muscle cells, non-
neuronal agrin (y0, z0) links the cytoskeleton to the basement
membrane through binding α-dystroglycan.31 32 Therefore we
investigated which of these two mechanisms was engaged for
the anabolic functions of agrin in chondrocytes. Treatment with
an antibody which blocks the interaction of α-dystroglycan with
agrin4 33 abrogated agrin-induced upregulation of SOX9 (ﬁgure
5A). Surprisingly, also LRP4 silencing by siRNA completely
inhibited agrin-induced SOX9 upregulation (ﬁgure 5B), suggest-
ing that both LRP4 and α-dystroglycan are required for
agrin-induced chondrocyte differentiation.
The requirement of LRP4 is unexpected because the (y0, z0)
variant of agrin has low afﬁnity for LRP4 and a reduced cap-
acity for clustering the AChR at the neuromuscular junction.34
However, overexpression of LRP4 alone also induced SOX9
expression in primary bovine chondrocytes (ﬁgure 5C), in
keeping with a previous report in ATDC5 cells.35 This and the
fact that deﬁciency of LRP4 result in a skeletal phenotype36
support a role for LRP4 in chondrocytic differentiation.
Interestingly, the overexpression or silencing of agrin in chon-
drocytes did not regulate the mRNA expression of LRP4 (ﬁgure
5D, E).
DISCUSSION
We have discovered that the (y0, z0) isoform of agrin is
expressed in the adult articular cartilage and is downregulated
in OA. We showed that agrin has an anabolic function in main-
taining chondrocyte differentiation and enhancing ECM pro-
duction in vitro and in vivo without inducing chondrocyte
hypertrophy or endochondral bone formation. We have found
that agrin-induced chondrocyte differentiation requires a unique
receptor/coreceptor repertoire including both α-dystroglycan
and LRP4 in articular chondrocytes.
Agrin function at the neuromuscular synapse requires the
binding of LRP4 and, indirectly, MuSK,3 5 37 whereas the func-
tion of agrin in muscle cells is mediated by its binding to
α-dystroglycan and laminin. It is thought that the differential
binding to these different receptor complexes is dependent on
the presence of the spliced inserts y and z, which confer high
afﬁnity for LRP4.26 38 In particular, structural data of the agrin–
LRP4–MuSK complex revealed that the z8 loop of rat neuronal
agrin was responsible for the primary agrin-LRP4 interaction,
preceding the formation of the tetramer in which two agrin–
LRP4 heterodimers interact and for MuSK-dependent signalling
at the neuromuscular junction.39 However, we previously
showed that the engagement of the coreceptors APP and APLP2
(also expressed by chondrocytes—ﬁgure 1A) can independently
interact with the z0 form of agrin as well as with LRP4,3 to
either stabilise the interaction of agrin with LRP4 or indirectly
recruit LRP4 into a larger agrin signalling complex and thereby
support its biological function as a BMP and WNT (Wingless
type MMTV integration site family member) signal modula-
tor.40 Taken together, these data suggest that an extended cell
surface receptor repertoire regulates the afﬁnity of agrin for dif-
ferent receptors and the interplay with other signalling pathways
including BMPs and WNTs to ﬁne-tune biological speciﬁcity in
the maintenance of articular cartilage.
In the skeletal context, as hypothesised in ﬁgure 6, LRP4
appears to modulate and coordinate fundamental signalling
pathways including WNTs and BMPs. While both these path-
ways are essential for the homeostasis and integrity of cartilage
throughout life,41–44 their excessive/inappropriate activation
drives cartilage breakdown.45 46 In humans, single nucleotide
polymorphisms in genes involved in the WNT and BMP path-
ways are associated with predisposition to develop OA.47 48
This modulation/coordination may take place through a multi-
tude of potential mechanisms including LRP4 acting as a recep-
tor for the WNTand BMP inhibitors sclerostin33 and Wise,40 as
well as the WNT inhibitor Dickkopf (DKK)-1,33 competing
Figure 3 Agrin (y0, z0)
overexpression resulted in increased
glycosaminoglycan production and an
upregulation of chondrocyte
differentiation markers. Primary bovine
chondrocytes were transfected with an
agrin, BMP-2 or GFP encoding
expression plasmid and cultured in
micromass for the time indicated. (A)
Alcian blue staining and quantiﬁcation
following guanidine extraction
expressed as total value and (B)
normalised by DNA content 5 days
after transfection. (C–E) Real-time PCR
analysis of SOX9, ACAN and COL2A1
mRNA expression levels over 5 days
(SOX9) and 7 days (COL2A1 and
ACAN) after transfection. Data are
mean±SEM, n=4. *p<0.05;
**p<0.005; ***p<0.0005 (unpaired t
test). ACAN, aggrecan; BMP-2, bone
morphogenetic protein-2; COL2A1,
collagen type II; GFP, green ﬂuorescent
protein
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Figure 4 Exogenous agrin (y0, z0) enhanced ectopic cartilage formation in vivo. Primary bovine chondrocytes were co-implanted in suspension
within the muscle of the thigh of nude mice with growth arrested COS7 cells overexpressing GFP or agrin. Cartilage implants were retrieved
after 2 weeks. (A) Safranin O staining showing increased accumulation of metachromatic cartilage matrix in the implants supplemented with
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area shown as a percentage. (F and G) Real-time PCR analysis of COL10A1 and MMP-13 mRNA expression levels of the implants using bovine-
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with the WNT coreceptors LRP5 and LRP6 and with the intra-
cellular WNT machinery. The overexpression of LRP4 alone in
primary articular chondrocytes was sufﬁcient to increase the
expression of SOX9 (ﬁgure 5C) in primary chondrocytes, sup-
ported chondrogenic differentiation and inhibited WNT signal-
ling in the ATDC5 cell line;35 in vivo, mice carrying a
hypomorphic LRP4 allele developed a signiﬁcant skeletal
phenotype.33 36
The identiﬁcation of a speciﬁc coreceptor repertoire and of a
speciﬁc agonist, agrin, capable of promoting the formation of
phenotypically stable hyaline-like cartilage resistant to vascular
invasion and endochondral bone formation in vivo, is a unique
therapeutic opportunity in cartilage-regenerative medicine and
in the ﬁeld of OA and opens a new exciting avenue of investiga-
tion to understand how high speciﬁcity of a biological effect is
achieved by modulating otherwise pleiotropic signalling
pathways.
Author afﬁliations
1Centre for Experimental Medicine and Rheumatology, William Harvey Research
Institute, Barts and the London School of Medicine and Dentistry, Queen Mary
University of London, London, UK
2Department of Surgical Research, NPIMR Y3, Harrow, UK
3The Francis Crick Institute (Mill Hill Laboratory), The Ridgeway, London, UK
4Department of Trauma and Orthopaedic Surgery, Royal London Hospital,
London, UK
5Department of Orthopaedics and IBMII: Molecular Cell Biology, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
A B C
D E
800
600
400
SO
X9
/b
-
a
ct
in
(as
%
 o
f c
on
tro
l)
LR
P4
/b
-
a
ct
in
(as
%
 o
f c
on
tro
l)
LR
P4
/b
-
a
ct
in
(as
%
 o
f c
on
tro
l)
SO
X9
/b
-
a
ct
in
(as
%
 o
f c
on
tro
l)
SO
X9
/b
-
a
ct
in
(as
%
 o
f c
on
tro
l)
200
GF
P +
 lgM
Sc
ram
ble
d
siR
NA
 1
siR
NA
 2
Ag
rinGF
P
BM
P-2
GF
P +
 Sc
ram
ble
d
GF
P +
 LR
P4
 siR
NA
Ag
rin
 + 
Sc
ram
ble
d
Ag
rin
 + 
LR
P4
 siR
NA pc
DN
A
Ag
rin
LR
P4
GF
P +
 a-
dy
str
og
lyc
an
Ag
rin
 + 
a-
dy
str
og
lyc
an
Ag
rin
 + 
IgM
800
600
400
200
0
800
600
400
200
200150
100
50
0
150
100
50
0
0
LRP4 LRP4
 



Figure 5 LRP4 and α-dystroglycan are both required for agrin-induced upregulation of SOX9. (A) Primary bovine chondrocytes were transfected
with an agrin expression plasmid or GFP as control and exposed to α-dystroglycan blocking antibody or a non-immune isotype control antibody and
assessed 5 days later for the expression of SOX9 mRNA by real-time PCR. (B) Real-time PCR analysis of SOX9 mRNA expression in chondrocytes
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Figure 6 Agrin and LRP4 are central
to a chondrogenic signalling network.
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SOX9 and its transcriptional targets
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pathways regulating chondrocyte
differentiation including WNTs and
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